[PDF] Top 20 Critical appraisal of ranibizumab in the treatment of diabetic macular edema

... ment Diabetic Retinopathy Study vision scores between 73 and 39 were randomized to receive sham treatments or ranibizumab injections of ...their ranibizumab doses doubled to ...monthly ... See full document

... by diabetic macular edema to compare the effects secondary to laser treatment, ranibizumab injections, or combination of the two ...ie, ranibizumab and sham laser (n = 116), ... See full document

... of ranibizumab PRN was positive ...for ranibizumab PRN (£4,897) representing a cost saving of ...for ranibizumab), ranibizumab PRN Table 4 Key treatment cost ... See full document

... The BCVA was recorded monthly for 1 year after the last loading injection. At the end of the follow-up period, the mean BCVA in eyes treated with aflibercept improved to 0.42 ± 0.28 and that in eyes treated with ... See full document

... NLR is a marker of inflammation-associated alterations in peripheral blood leukocytes; thus, it has been compre- hensively investigated as a potential indicator of systemic inflammation [19]. It has been shown to have a ... See full document

... other treatment for macular edema within the previous 10 ...the treatment has not yet been approved in ...the macular map analysis protocol of the RS-3000 SD-OCT was ...Early ... See full document

... three treatment arms in Protocol T; however, a post hoc analysis performed demonstrated a statistically significant increased frequency in cardiac and vascular disorders in the ranibizumab ... See full document

... the treatment of DME and results from Protocol T, many ophthalmolo- gists are switching patients from ranibizumab or beva- cizumab to aflibercept, especially those with minimal or incomplete response to the ... See full document

... mg ranibizumab at monthly intervals at the investiga- tor’s discretion for 2 ...receiving ranibizumab (n = 190); and ranibizumab-naïve group (n = ...the ranibizumab-treated group and the ... See full document

... develop diabetic macular edema (DME) which, if left untreated, is a major cause of vision impairment and legal blindness in patients with ...5 Ranibizumab is a recombinant humanized monoclonal ... See full document

... The analysis pursued is characterized by specific draw- backs and limitations. Since the analysis was undertaken from the perspective of Greek Health Care Insurance Fund, only direct medical costs for the ... See full document

... of treatment, and comorbid ocular and systemic conditions (eg, glaucoma, vascular disease) may all factor into the decision-making ...(eg, ranibizumab + laser for ... See full document

... following diabetic retinopathy, and macular edema is the most frequent cause of visual impairment in patients with ...the treatment of BRVO-associated macular ...with macular ... See full document

... Several systemic risk factors have been identified in popu- lation-based epidemiological studies. In patients <30 years old, independent risk factors for DME included duration of diabetes, proteinuria, gender, history ... See full document

... the treatment of DME at the Royal Surrey County Hospital (Guildford, UK) during the period May 1, 2011 to December 31, 2013, who had at least 1 year of ...of treatment, patient informed consent was waived ... See full document

... SDM treatment was necessary in 43 eyes ...persistent macular edema and worsening of visual acuity on follow-up ...the macular area after maximum argon laser photocoagula- tion (Figure ...for ... See full document

... In conclusion, rituximab has improved the management of CLL and has become a critical agent in most combination regimens. It increases CR and ORRs, and prolongs PFS. FCR appears to be the best front-line regimen ... See full document

... Early Treatment Diabetics Retinopathy Study (ETDRS) fields) was determined automatically and analyzed by OCT software, by generating images using the Macular Cube 512 × 128 scan over 6 × 6 mm area, the cube ... See full document

... 25.8% and businessmen and women 24.5%. Total injections were 2443, given during the study period. Anti-VEGF agents used were Bevacizumab (2278; 93.2%) and Ranibizumab (165; 6.8%). Indications for injection were: ... See full document

... (Early Treatment Diabetic Retinopathy Study [ETDRS] letter score, ≤ 58; approximate Snellen equivalent, 20/80 or worse) than for those with better visual ... See full document